GAINESVILLE, FL – neuropacsTM, a leading innovator in medical diagnostics, is excited to announce the acquisition of an exclusive option agreement for a groundbreaking diagnostic technology for Alzheimer’s disease developed at the University of Florida. This innovative technology, spearheaded by neuropacsTM‘s Co-Founder and Chief Scientific Officer, David Vaillancourt, has the potential to revolutionize early detection and intervention for Alzheimer’s disease.
The groundbreaking research, recently published by the University of Florida, highlights a novel link between abnormal blood levels of amyloid—a protein associated with Alzheimer’s disease—and subtle changes in brain microstructures detected through a specialized MRI technique known as diffusion MRI, or “free-water” imaging. These findings, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, suggest a promising new avenue for early detection of Alzheimer’s disease in individuals with no clinical signs.
This is a significant breakthrough in Alzheimer’s disease detection, with findings demonstrating that free-water imaging can detect early stages of decline in brain tissue and microstructures, even in individuals with negative PET scans for amyloid plaques. “Our findings suggest there seem to be events occurring both in the blood and in the brain before you get amyloid positivity in the brain,” commented senior author David Vaillancourt, Ph.D., professor and chair of UF’s department of applied physiology and kinesiology.
“neuropacsTM is proud to collaborate with the University of Florida to advance this cutting-edge diagnostic technology for Alzheimer’s disease,” said Martin Handfield, CEO at neuropacsTM. “We believe that this innovative approach has the potential to transform the landscape of Alzheimer’s diagnosis and pave the way for earlier intervention and improved patient outcomes.”
neuropacsTM is committed to advancing this transformative diagnostic technology for Alzheimer’s disease and looks forward to leveraging its expertise in medical diagnostics to accelerate the translation of this research into clinical practice.
For more information about neuropacsTM and its revolutionary capabilities, visit neuropacs.com.
About neuropacsTM:
neuropacsTM is a pioneering medical technology company dedicated to developing innovative solutions for neurological diagnostics. With a commitment to advancing healthcare through cutting-edge technologies, neuropacsTM remains at the forefront of revolutionizing clinical care standards.
Forward-Looking Statements
This communication includes express and implied “forward-looking statements.” Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. By their nature, these statements are subject to numerous risks and uncertainties, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law.